Once weekly administered drugs represent a significant innovation in the pharmacological management of T2D, as demonstrated mainly by incretin-based injective treatments, such as glucagon-like peptide 1 receptor agonists (GLP-1RAs) and dual GLP-1 and glucose-dependent insulinotropic peptide receptor agonists [14,15,16,17]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.